TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8325065

Group type: EXPERIMENTAL
Intervention: Oral theophylline (400 mg for 2 weeks, followed by 600 mg for 2 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3793027

Group type: EXPERIMENTAL
Intervention: Axillary extract from donor males
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blank/ethanol applications
Number of subjects: 0
Study: 30172428

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Combined Training (HIIT + MICT)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 109
Study: 26943113

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Daily Occupational Performance (CO‐OP)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual occupational therapy
Number of subjects: 35
Study: 24690533

Group type: EXPERIMENTAL
Intervention: Mailed explanatory primer letter designed to encourage research participation
Number of subjects: 1062

Group type: COMPARATOR
Intervention: No primer letter
Number of subjects: 1062
Study: 22401286

Group type: EXPERIMENTAL
Intervention: 80/20 prior knowledge cue
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50/50 prior knowledge cue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brain activity in dorsolateral pFC, inferior frontal junction, anterior insula, inferior parietal lobule, intraparietal sulcus, head of the caudate, posterior cingulate cortex, and fusiform gyrus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fronto-parietal and anterior insula ROIs
Number of subjects: 0
Study: 20617227

Group type: EXPERIMENTAL
Intervention: Composite resin cement
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Acrylic/urethane cement
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Zinc oxide eugenol cement
Number of subjects: 3
Study: 19000203

Group type: EXPERIMENTAL
Intervention: Feedback from a same-gender peer
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Feedback from an other-gender peer
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Feedback from a gender-unidentified peer
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Positive feedback after initial failure
Number of subjects: 58
Study: 15094031

Group type: EXPERIMENTAL
Intervention: standard treatment + soma
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: standard treatment + relaxation training
Number of subjects: 191

Group type: COMPARATOR
Intervention: waiting control group
Number of subjects: 191
Study: 11765290

Group type: EXPERIMENTAL
Intervention: Adderall (ADL)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo, 5 mg, 10 mg, 15 mg (various doses)
Number of subjects: 177
Study: 9290370

Group type: EXPERIMENTAL
Intervention: DACE group (drainage, air injection, cryotherapy, and explant)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CDAE group (cryotherapy, drainage, air injection, and explant)
Number of subjects: 80
Study: 8115115

Group type: EXPERIMENTAL
Intervention: Computerized pachymetry (DGH 1000) measurements by three randomized operators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different patient positions (orthostatic and clinostatic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corneal marking before and after measurements
Number of subjects: 0
Study: 3521524

Group type: EXPERIMENTAL
Intervention: Doxepin hydrochloride (mean maximal dose: 105 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (mean maximal dose: 128 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Doxepin hydrochloride
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30955907

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulation
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sham (light touch approach)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (simple observation)
Number of subjects: 67
Study: 28566124

Group type: EXPERIMENTAL
Intervention: Topical melatonin 12.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical melatonin 0.5% and 2.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo and no treatment
Number of subjects: 0
Study: 26230471

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 5 mmol/L magnesium sulfate (MgSO4) solution for 14 days
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard treatment (Control group)
Number of subjects: 73
Study: 23733674

Group type: EXPERIMENTAL
Intervention: Nimotuzumab combined with docetaxel‐cisplatin‐fluorouracil regimen
Number of subjects: 9
Study: 22357799

Group type: EXPERIMENTAL
Intervention: Goal setting intervention (Exp, n = 16)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Therapist-led exercise therapy group (C1, n = 16)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-therapist-led exercise therapy group (C2, n = 16)
Number of subjects: 48
Study: 19502459

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 42
Study: 17720117

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.26% wt/vol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.30% wt/vol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.34% wt/vol)
Number of subjects: 0
Study: 15323598

Group type: EXPERIMENTAL
Intervention: St. John's wort extract
Number of subjects: 112

Group type: COMPARATOR
Intervention: Antidepressant treatment
Number of subjects: 112
Study: 10895973

Group type: EXPERIMENTAL
Intervention: FES-biofeedback
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intensive pelvic floor muscle exercise
Number of subjects: 60
Study: 9495978

Group type: EXPERIMENTAL
Intervention: Aspirin taken preventively before adverse reactions of alpha-IFN
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional routines of aspirin administration
Number of subjects: 0
Study: 8374284

Group type: EXPERIMENTAL
Intervention: Allogeneic blood transfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autologous blood transfusion
Number of subjects: 0
Study: 3751672

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 69

Group type: COMPARATOR
Intervention: metrizoate
Number of subjects: 69
Study: 29641669

Group type: EXPERIMENTAL
Intervention: Leaflet group (intervention)
Number of subjects: 702
Study: 28477289

Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.2–1.8 mg/kg/day) for 1 year, followed by randomization to atomoxetine for 6 months (n=81)
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Atomoxetine (80–100 mg/day) for 6 months, followed by randomization to atomoxetine for 6 months (n=266)
Number of subjects: 687

Group type: COMPARATOR
Intervention: Placebo (n=82 in Study 1; n=258 in Study 2)
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 687
Study: 24807650

Group type: EXPERIMENTAL
Intervention: Redesigned rural insurance benefit package
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of insurance intervention and capitation budget with pay-for-performance
Number of subjects: 0
Study: 23910745

Group type: EXPERIMENTAL
Intervention: Reminiscence intervention (8 sessions)
Number of subjects: 0
Study: 21719058

Group type: EXPERIMENTAL
Intervention: First academic quarter surgical patients
Number of subjects: 89473

Group type: COMPARATOR
Intervention: Control group surgical patients
Number of subjects: 89473

Group type: EXPERIMENTAL
Intervention: First academic quarter surgical patients undergoing artery bypass graft
Number of subjects: 89473

Group type: COMPARATOR
Intervention: Control group surgical patients undergoing artery bypass graft
Number of subjects: 89473

Group type: EXPERIMENTAL
Intervention: First academic quarter surgical patients undergoing repair bowel opening
Number of subjects: 89473

Group type: COMPARATOR
Intervention: Control group surgical patients undergoing repair bowel opening
Number of subjects: 89473
Study: 18339054

Group type: EXPERIMENTAL
Intervention: Low Sugar Low Yeast (LSLY) dietary intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Healthy Eating (HE) dietary intervention
Number of subjects: 52
Study: 16551154

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral group therapy
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral bibliotherapy
Number of subjects: 117

Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 117
Study: 12663564

Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 56

Group type: COMPARATOR
Intervention: In-person
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups (Telemedicine and In-person)
Number of subjects: 56
Study: 11109693

Group type: EXPERIMENTAL
Intervention: Home safety assessment
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 252
Study: 9193431

Group type: EXPERIMENTAL
Intervention: Ser447-Stop allele carriers (heterozygotes and homozygotes)
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Ser447-Stop allele carriers using beta-blockers
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Ser447-Stop allele carriers not using beta-blockers
Number of subjects: 820
Study: 1604251

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (1000 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low-dose methylprednisolone (375 mg)
Number of subjects: 17
Study: 31830078

Group type: EXPERIMENTAL
Intervention: Peer-led interpersonal communication (IPC) intervention
Number of subjects: 2430

Group type: COMPARATOR
Intervention: Mass media campaign alone (Control)
Number of subjects: 2430

Group type: EXPERIMENTAL
Intervention: IPC attendance
Number of subjects: 2430

Group type: EXPERIMENTAL
Intervention: General knowledge and awareness in the community (combined intervention)
Number of subjects: 2430
Study: 28161789

Group type: EXPERIMENTAL
Intervention: Pancreatic extract (Creon®) 50,000 units with meals and 25,000 units with snacks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pancreatic extract (Creon®)
Number of subjects: 18
Study: 26548851

Group type: EXPERIMENTAL
Intervention: Cusum
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 25107319

Group type: EXPERIMENTAL
Intervention: High trait anxious individuals
Number of subjects: 2

Group type: COMPARATOR
Intervention: Low trait anxious individuals
Number of subjects: 2
Study: 23101257

Group type: EXPERIMENTAL
Intervention: Combined antihypertensive therapy (long-acting verapamil combined with slow-release indapamide)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined antihypertensive therapy (long-acting verapamil combined with enalapril)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (verapamil plus indapamide)
Number of subjects: 24
Study: 19446147

Group type: EXPERIMENTAL
Intervention: Standard-dose prednisone regimen (1 mg/kg daily)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) combined with lower prednisone dose (0.5 mg/kg daily)
Number of subjects: 41
Study: 18631345

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Probiotic groups (Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 16447665

Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion
Number of subjects: 80

Group type: COMPARATOR
Intervention: TCM and western drugs (Control)
Number of subjects: 80
Study: 11822926

Group type: EXPERIMENTAL
Intervention: Isotonic hydration (0.9% saline)
Number of subjects: 1620

Group type: COMPARATOR
Intervention: Half-isotonic hydration (0.45% sodium chloride plus 5% glucose)
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: Isotonic hydration
Number of subjects: 1620

Group type: COMPARATOR
Intervention: Half-isotonic hydration
Number of subjects: 1620
Study: 10413725

Group type: EXPERIMENTAL
Intervention: High ambient relative humidity (HRH) (85% relative humidity)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low ambient relative humidity (LRH) (16% relative humidity)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High ambient relative humidity (HRH)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low ambient relative humidity (LRH)
Number of subjects: 12
Study: 7720462

Group type: EXPERIMENTAL
Intervention: Gabexate mesilate
Number of subjects: 5
Study: 2127016

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) as add-on therapy
Number of subjects: 23
Study: 6945060

Group type: COMPARATOR
Intervention: Vincristine (VCR) 2 mg/m2 on day 1 and Cyclophosphamide (CP) 450 mg/m2 on days 2 and 3 (two-drug regimen)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Vincristine (VCR) 2 mg/m2 on day 1, Cyclophosphamide (CP) 450 mg/m2 on days 2 and 3, and BCNU 50 mg on days 2 and 3 (three-drug regimen)
Number of subjects: 38
Study: 31580695

Group type: EXPERIMENTAL
Intervention: Ischemic Compression (IC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dry Cupping
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination Therapy (IC + Dry Cupping)
Number of subjects: 24
Study: 31103401

Group type: EXPERIMENTAL
Intervention: Aversive advice during PCI procedure
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (usual advice on quitting smoking)
Number of subjects: 66
Study: 28260863

Group type: COMPARATOR
Intervention: Glimepiride alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Glimepiride in combination with rosuvastatin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rosuvastatin alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rosuvastatin in combination with glimepiride
Number of subjects: 24
Study: 25642461

Group type: EXPERIMENTAL
Intervention: Nano-filled resin-modified glass ionomer (Ketac Nano; KN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional resin-modified glass ionomer (Vitremer; VR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both materials (KN and VR)
Number of subjects: 60
Study: 23676106

Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture (once a day for 6 months)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Oral metformin (250 mg three times daily in the first week, followed by 500 mg three times daily thereafter)
Number of subjects: 86
Study: 20972351

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg) for 6 months in patients with high baseline LDL-C (≥ 100 mg/dL)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg) for 6 months in patients with low baseline LDL-C (< 100 mg/dL)
Number of subjects: 180
Study: 20361714

Group type: EXPERIMENTAL
Intervention: 3 g of cardamom powder administered in two divided doses for 12 weeks
Number of subjects: 20
Study: 17234798

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia (IH) followed by continuous hypoxia (CH) for 12 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Continuous hypoxia (CH) for 12 days without prior intermittent hypoxia (IH)
Number of subjects: 14
Study: 14746950

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 180
Study: 11282259

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Memantine (0.16 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9091325

Group type: EXPERIMENTAL
Intervention: Laparotomy
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Laparoscopic procedure
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Partial or total salpingectomy
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Single-dose methotrexate
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Conservative surgery
Number of subjects: 5145
Study: 7699618

Group type: EXPERIMENTAL
Intervention: Drug treatment strategies
Number of subjects: 97
Study: 3129807

Group type: EXPERIMENTAL
Intervention: DDAVP 0.4 microgram kg‐1 intravenous (i.v.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: DDAVP 0.4 microgram kg‐1 subcutaneous (s.c.)
Number of subjects: 6
Study: 28993287

Group type: EXPERIMENTAL
Intervention: Certified diabetes educators (CDEs) implementing standardized protocols to intensify treatment
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study: 26957281

Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg/day)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study: 26434249

Group type: EXPERIMENTAL
Intervention: Low dose of APE (71.64-72.36 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High dose of APE (119.64-120.36 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gemfibrozil (300 mg/day)
Number of subjects: 60
Study: 23552120

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg thrice weekly after dialysis for 4 months)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (4 months prior to spironolactone)
Number of subjects: 14
Study: 24843534

Group type: EXPERIMENTAL
Intervention: olmesartan (20mg/day)/azelnidipine (16mg/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: olmesartan (20mg/day)/trichlormethiazide (1mg/day)
Number of subjects: 39
Study: 18218298

Group type: EXPERIMENTAL
Intervention: Test formulation (dexibuprofen 400 mg by Emcure Pharmaceuticals)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation (dexibuprofen 400 mg by Genus Pharmaceuticals)
Number of subjects: 24
Study: 16272449

Group type: EXPERIMENTAL
Intervention: 50 mg intravenous hydrocortisone every 6 h
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 12808270

Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg daily)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Candesartan plus probucol (500 mg daily)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study: 10232493

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (5 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 8561323

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tracheal Tube (TT)
Number of subjects: 60
Study: 1681355

Group type: EXPERIMENTAL
Intervention: Atenolol plus isosorbide mononitrate
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Atenolol plus nifedipine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Triple therapy (atenolol plus isosorbide mononitrate and nifedipine)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Atenolol alone
Number of subjects: 18
Study: 6307330

Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (0.5 mg i.v.)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (1 mg i.v.)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 28644680

Group type: EXPERIMENTAL
Intervention: Exploratory factor analysis with the exploratory group
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Confirmatory factor analysis
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Validation group
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: SCORS‐G scales
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: SCORS‐G
Number of subjects: 488
Study: 27002748

Group type: EXPERIMENTAL
Intervention: 6-week peer-led exercise and education intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational workbooks
Number of subjects: 0
Study: 24989831

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention with diet counselling and physical activities
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 360
Study: 22156966

Group type: EXPERIMENTAL
Intervention: Injectable contraception
Number of subjects: 3354

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 3354

Group type: EXPERIMENTAL
Intervention: Condoms
Number of subjects: 3354

Group type: EXPERIMENTAL
Intervention: Intrauterine devices, implantable methods, surgical sterilization
Number of subjects: 3354
Study: 20554708

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg annually
Number of subjects: 7765

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7765
Study: 18936231

Group type: EXPERIMENTAL
Intervention: Vitamin A (240 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 15797158

Group type: EXPERIMENTAL
Intervention: Short educational package on communication skills (commented video footage)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 36
Study: 12579102

Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diltiazem (180 mg)
Number of subjects: 30
Study: 11310904

Group type: EXPERIMENTAL
Intervention: Propofol containing 0.005% EDTA (propofol EDTA)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Non-EDTA sedative agents
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 210
Study: 8612407

Group type: EXPERIMENTAL
Intervention: Reconstituted high-density lipoprotein preparation (2 mg/mL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (6 age- and gender-matched subjects)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Patients with infections
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Patients in the ICU
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Patients in the ICU over 8 days
Number of subjects: 32
Study: 1348620

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.015 mg/kg (priming) followed by 0.285 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vecuronium 0.3 mg/kg (single dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.3 mg/kg (both groups)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.75 mg/kg for reversal
Number of subjects: 30